DQIP Intervention
BehavioralThe DQIP intervention comprises of:
- Educational outreach
- Information technology application
- Financial incentives
NCT Number: NCT01425502
A cluster randomised controlled trial to test the effectiveness of an informatics tool, educational and financial incentives to reduce high risk prescribing of non-steroidal anti-inflammatory drugs and anti-platelet agents.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
NHS Fife, General Practices Across Fife, United Kingdom
The trial described here is part of a programme which aimed to design a complex, primary care prescribing safety improvement intervention and test its effectiveness in a randomised controlled trial.
Non-steroidal anti-inflammatory drugs (NSAIDs) and antiplatelet drugs such as low dose aspirin and clopidogrel are responsible for a significant proportion of hospital admissions due to preventable adverse drug events (ADE), and are the drugs most commonly associated with fatal ADEs. Previous research has identified groups of patients and patterns of co-prescription in which use of these drugs is particularly high-risk , and national prescribing and safety guidance has embedded this research in clear recommendations to either avoid prescribing or to do so only when there is no alternative, and with caution. In previous epidemiological work, we have shown that high-risk use of NSAIDs, aspirin and clopidogrel is common, and pilot work in four practices has shown that focused review of prescribing by the practice reduced the targeted high-risk NSAID prescribing by approximately 40% after one round of feedback. This effect size is consistent with the PINCER trial where the intervention was a pharmacist facilitated review process.
We hypothesise that a multi-faceted intervention comprising of (1) educational outreach, (2) use of an informatics tool to monitor prescribing patterns at practice level and to prompt and facilitate the review of individual patients at risk of ADEs and (3) a small financial incentive to review patients will reduce rates of high-risk prescribing.
The specific research questions addressed by the trial are:
The trial will use a stepped-wedge design, which is particularly suited to a sequential roll-out of an intensive and informatics based intervention focusing on patient safety. In this design, all participating practices receive the intervention, but are randomised to a starting time. At the point of entering the intervention phase of the trial, all practices will receive an educational outreach visit which will include training in the use of the informatics tool.
The informatics tool will provide regular feedback of any change in rates of high-risk prescribing for each individual measure and the composite measure, with the ability to drill-down to individual patient level and review a summary of each patient's relevant conditions and prescribing.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The DQIP intervention comprises of:
Time frame: 8 weeks
The primary and all secondary outcome measures will be measured in each practice at 8 weekly intervals (reflecting that all measures assess high risk prescriptions for NSAIDs and antiplatelets in the last 8 weeks). At the time of initial data extraction, 8 weekly intervals will be constructed for the 12 months before the intervention start date.
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 48 weeks
Time frame: 48 weeks
Time frame: 48 weeks
Time frame: 48 weeks
Time frame: 48 weeks
Time frame: 48 weeks
Time frame: 48 weeks
Time frame: 48 weeks
Time frame: 48 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
Time frame: 8 weeks
University of Dundee
Other
Data-driven Quality Improvement in Primary Care: Cluster Randomised Controlled Trial to Test the Effectiveness of a Multifaceted Intervention in Reducing High Risk Prescribing of Non-steroidal Anti-inflammatory Drugs and Antiplatelet Agents
Acronym: DQIP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01722916
Drug Safety
Chicago, Illinois, United States
View Trial DetailsNCT06644105
Drug Metabolism, Drug Safety
Chengdu, China
View Trial DetailsNCT01669824
Aspirin, Drug Safety
Multiple Locations, Germany
View Trial DetailsNCT01367873
Drug Safety
Fargo, North Dakota, United States
View Trial Details